Answers are grounded in this paper and cite their sources.
Evaluates acoramidis efficacy in Japanese adults with transthyretin amyloid cardiomyopathy, suggesting its potential benefits.
Background: This multicenter open-label single-arm 2-part prospective Phase 3 trial (NCT04622046) evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of acoramidis, an oral, highly selective transthyretin (TTR) stabilizer, in Japanese patients with wild-type or hereditary symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM).
No takes yet. Share an insight, caveat, or question.
Endo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: